Hover to zoom
GLP-1 & MetabolicSynthetic dual GLP-1 / GIP receptor agonist
Tirzepatide
$39.99
10 mg· 4 strengths availableTirzepatide is a synthetic peptide engineered to engage two incretin receptors — the glucose-dependent insulinotropic polypeptide (GIP) receptor and the GLP-1 receptor — from a single molecule.
That dual activity makes it a common reference compound in laboratory studies comparing single-receptor and multi-receptor agonism within metabolic signaling pathways.
Research areas
GIP receptor activityGLP-1 receptor signalingDual-agonist comparisonMetabolic pathway research
Form: Lyophilized (freeze-dried)
- Compound class
- Synthetic dual GLP-1 / GIP receptor agonist
- Research category
- GLP-1 & Metabolic
- SKU
- NVR-TIRZEPATIDE-10MG
- Alternate name
- Tirzep
- CAS
- 2023788-19-2
- Appearance
- White to off-white lyophilized powder
- Storage
- Store lyophilized at −20 °C. Protect from light and moisture.
Research use only
Select strength
Cost per mg shown for each option
1
$39.99per 10 mg$4.00/mg
For research use only — not for human or animal consumption.
Supplied solely for legitimate laboratory and research purposes. Not for medical or veterinary use, diagnosis, treatment, or prevention of disease.
Research Grade
Batch Documentation
Research Use Only
U.S.-Based Fulfillment
What you should know
More detail on Tirzepatide.
Analytical values reflect per-lot documentation and appear once a batch is released.
Compound
Tirzepatide is built on a GIP-based backbone with substitutions and a lipid side chain that extend circulation time in preclinical models. Its research value comes from the ability to probe two incretin receptors simultaneously, allowing investigators to separate GIP-driven from GLP-1-driven effects in cultured cells and receptor assays. Published work characterizes its relative potency at each receptor and its signaling profile compared with selective agonists. Investigation of multi-receptor incretin pharmacology remains active, and this material is supplied strictly for that experimental context.
Peptide class
Synthetic dual GLP-1 / GIP receptor agonist
Mechanism (research context)
As a dual GLP-1 / GIP receptor agonist, tirzepatide simultaneously activates both incretin receptors in research models — a mechanism of interest to investigators studying combined incretin pharmacology.
Why it is studied
Tirzepatide is one of the most extensively studied dual-agonist research peptides in current metabolic literature.
Current areas of research
GIP receptor activityGLP-1 receptor signalingDual-agonist comparisonMetabolic pathway research
Topics reflect published preclinical and in vitro research. Reference only — not a claim of clinical outcomes.
Scientific background
Tirzepatide represented an important step in metabolic peptide research by combining GLP-1 and GIP receptor engagement in a single molecule.
It has become a reference compound in the dual-agonist metabolic literature and paved the way for triple-agonist peptides such as retatrutide.
Related
View all →Related research materials
Cagrilintide
10 mg
Long-acting amylin analog studied for amylin and calcitonin receptor signaling in laboratory models.
$99.99
DetailsCagrilintide / Semaglutide
5/5 mg
Research blend pairing an amylin analog with a GLP-1 receptor agonist for combined-pathway studies.
$119.99
DetailsHGH Fragment 176-191
5 mg
Unmodified C-terminal growth-hormone fragment used in comparative adipose-tissue research.
$69.99
DetailsTirzepatide
10 mg · $39.99